Mesoporous Silica Nanoparticle Based Controlled Release, Drug Delivery, and Biosensor Systems

ChemInform ◽  
2007 ◽  
Vol 38 (49) ◽  
Author(s):  
Brian G. Trewyn ◽  
Supratim Giri ◽  
Igor I. Slowing ◽  
Victor S.-Y. Lin
Keyword(s):  
Drug Delivery ◽  
Controlled Release ◽  
Mesoporous Silica ◽  
Silica Nanoparticle ◽  
Mesoporous Silica Nanoparticle ◽  
Release Drug

A Review on Application of Multifunctional Mesoporous Nanoparticles in Controlled Release of Drug Delivery

2014 ◽  
Vol 781 ◽  
pp. 17-24 ◽  
Author(s):  
Pragnesh N. Dave ◽  
Lakha V. Chopda
Keyword(s):  
Drug Delivery ◽  
Controlled Release ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Silica Nanoparticle ◽  
Disease Diagnosis ◽  
Ammonium Bromide ◽  
Composition Material ◽  
Mesoporous Silica Nanoparticle

In the early 1990s the discovery of the MCM-41 and the M41S family of mesoporous materials had open new era in the chemistry and biology. They have prominent application inbiotechnological, biomedical and heterogeneous catalysts. Mesoporous silica nanoparticles (MSNs) exhibit unique structural features like as their large surface areas, tunable pore sizes in nanometer and well-defined surface properties. MSN materials which are comprised of a honeycomb-like porous structure with hundreds of empty mesoporous channel that are able to encapsulate relatively large amounts of biomolecules. They are ideal candidate for constructing multifunctional materials that encapsulate a variety of functional nanostructured materials. Multifunctional MSN materials have become one of the most attractive areas in nanobiotechnology and nanomedicine for various disease diagnosis and therapy. Multifunctional MSN have been successfully developed as a multifunctional platform to deliver therapeutic and diagnostic agents. Multifunctional MSNs are a highly promising platform for intracellular controlled release of drugs. In this review we discuss the recent developments in design and fabrication of multifunctional mesoporous silica nanoparticles in as efficient drug delivery applications such as the site-specific delivery and intracellular controlled release of drugs.Abbreviations;APTES; 3-aminopropyl triethoxy sialne, ATP; Adenosine triphospahate, CD; cyclodextrinCPT; camptothecin, CS; Chitosan,CTAB; cyltrimethylammonium bromide,DNA; Deoxyribonucleic acid,DOX; doxorubicin,EDC; 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide,FD; fluorescein disodium,FSP;Fluroscent particle ,IBU;ibuprofen,MCM; mobil composition material, MPS; 3-trimethoxylsilyl propyl methacrylate, MS; mesoporous silica,MSN; mesoporous silica nanoparticle, MSNs; mesoporous silica nanoparticles,MSNP; mesoporous silica nanoparticle,NPS; nanoparticles;PFDTES;perfluorodecyltriethoxysilane, PAA; polyacrylic acid,PR;photo responsive,PMAA; polymethyl methacrylate,SBF; simulated body fluid,TEOS;tetraethyl orthosilicate,TUNA;Thio undecyl-tetraethyleneglycoestero-nitrobenzylethyldimethyl ammonium bromide.

scholarly journals Mesoporous silica nanoparticle-based intelligent drug delivery system for bienzyme-responsive tumour targeting and controlled release

2018 ◽  
Vol 5 (1) ◽  
pp. 170986 ◽  
Author(s):  
Yang Zhang ◽  
Juan Xu
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Controlled Release ◽  
Drug Release ◽  
Mesoporous Silica ◽  
Cancer Cell ◽  
Silica Nanoparticle ◽  
Cell Targeting ◽  
Mesoporous Silica Nanoparticle ◽  
Cancer Cell Targeting

This paper proposes a novel type of multifunctional envelope-type mesoporous silica nanoparticle (MSN) to achieve cancer cell targeting and drug-controlled release. In this system, MSNs were first modified by active targeting moiety hyaluronic acid (HA) for breast cancer cell targeting and hyaluronidases (Hyal)-induced intracellular drug release. Then gelatin, a proteinaceous biopolymer, was grafted onto the MSNs to form a capping layer via glutaraldehyde-mediated cross-linking. To shield against unspecific uptake of cells and prolong circulation time, the nanoparticles were further decorated with poly(ethylene glycol) polymers (PEG) to obtain MSN@HA-gelatin-PEG (MHGP). Doxorubicin (DOX), as a model drug, was loaded into PEMSN to assess the breast cancer cell targeting and drug release behaviours. In vitro study revealed that PEG chains protect the targeting ligand and shield against normal cells. After reaching the breast cancer cells, MMP-2 overpressed by cells hydrolyses gelatin layer to deshield PEG and switch on the function of HA. As a result, DOX-loaded MHGP was selectively trapped by cancer cells through HA receptor-mediated endocytosis and subsequently release DOX due to Hyal-catalysed degradation of HA. This system presents successful bienzyme-responsive targeting drug delivery in an optimal fashion and provides potential applications for targeted cancer therapy.

A Dual-Responsive Mesoporous Silica Nanoparticle for Tumor-Triggered Targeting Drug Delivery

Small ◽  
2013 ◽  
Vol 10 (3) ◽  
pp. 591-598 ◽  
Author(s):  
Dong Xiao ◽  
Hui-Zhen Jia ◽  
Jing Zhang ◽  
Chen-Wei Liu ◽  
Ren-Xi Zhuo ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Silica Nanoparticle ◽  
Mesoporous Silica Nanoparticle ◽  
Dual Responsive

scholarly journals Ultrasound-mediated cavitation-enhanced extravasation of mesoporous silica nanoparticles for controlled-release drug delivery

2018 ◽  
Vol 340 ◽  
pp. 2-8 ◽  
Author(s):  
Juan L. Paris ◽  
Christophoros Mannaris ◽  
M. Victoria Cabañas ◽  
Robert Carlisle ◽  
Miguel Manzano ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Controlled Release ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Mesoporous Silica Nanoparticles ◽  
Release Drug
Sign in / Sign up

Export Citation Format

Share Document